Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19
02 août 2023 08h00 HE
|
Enlivex Therapeutics Ltd
Data published in Frontiers in Immunology show a robust safety profile and rapid resolution from ARDS and parallel resolution of inflammation markers and elevated cytokines/chemokines, as well as...
Global Acute Respiratory Distress Syndrome Market Size To Exceed USD 2137.6 Billion By 2030 | CAGR of 7.9%
03 avr. 2023 12h00 HE
|
SPHERICAL INSIGHTS LLP
New York, United States , April 03, 2023 (GLOBE NEWSWIRE) -- The Global Acute Respiratory Distress Syndrome Market Size to grow from USD 980.4 million in 2021 to USD 2,137.6 million by 2030, at a...
Acute Respiratory Distress Syndrome Therapeutics Market Size (2022-2030) Share, Industry Trends, Growth, Challenges, and Forecast: Growth Plus Reports
18 janv. 2023 06h11 HE
|
Growth Plus Reports
Pune, Jan. 18, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global acute respiratory distress syndrome therapeutics market is expected to clock US$...
New Edition | Acute Respiratory Distress Syndrome Market Report : Global Industry is Growing and Anticipated to Reach USD 18.56 BN by 2029 | Douglas Insights
06 déc. 2022 02h15 HE
|
Douglas Insights
Isle of Man, Dec. 06, 2022 (GLOBE NEWSWIRE) -- The Douglas Insights Engine is the world’s first market comparison engine. People from all industries, including market analytics, research, business,...
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome
20 mai 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
Brazil Phase 2 Pivotal clinical trial of COVI-MSC is now authorized to proceed.The study will compare therapy using mesenchymal stem cells to placebo (and standard of care) in 100 COVID-19 patients...
Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
25 mars 2021 15h58 HE
|
Sorrento Therapeutics, Inc.
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3rd COVI-MSC infusionPreparations are ongoing for initiating Phase 2 placebo-controlled...
Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
26 janv. 2021 19h09 HE
|
Sorrento Therapeutics, Inc.
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse events noted for any patient treated to date SAN DIEGO, Jan. 26, 2021 ...
Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue Therapies
12 oct. 2020 17h21 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has entered into an exclusive license agreement with Personalized Stem...
[2020-2026] Acute Respiratory Distress Syndrome Treatment Market Size, Share, Growth, Revenue, Potential, Analysis Report
24 sept. 2020 06h03 HE
|
Fortune Business Insights
Pune, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Advancements in stem cell research is a major driving factor for the global acute respiratory distress syndrome treatment market growth. According to the...
Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress
01 juin 2020 16h03 HE
|
NeuroRx
First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100Clinical trial to enroll 144 patients total with expansion to additional sites including the...